Everist Health, formerly Everist Genomics, is starting to hit its stride in sales of its cardiac-testing technology.
The Ann Arbor-based firm makes AngioDefender, which helps doctors measure the risk of stroke and cardiovascular disease. To put it simply, AngioDefender gives people medical information about their heart in an easy-to-understand way without the technical jargon. It will tell the user how old the heart is compared to its actual age. Check out a video on it here.
"You may be 45 but your heritage might be 55," says Randal Charlton, director of Everist Health.
Everist Health has hired six people around the world over the last year, bringing its staff to 12 full-time employees, 20 consultants, and the occasional intern. It is selling AngioDefender in India and is getting ready to penetrate the markets in Germany, Austria, Switzerland, United Kingdom, and Canada.
"We are now in go-to market mode," Charlton says.
Everist Health is also working to get the green light in the U.S. from the FDA. It is in the midst of organizing a clinical trial and hopes to get approval from the FDA by next year.
"We expect to start it very soon," Charlton says. "Certainly before the end of the year."
Everist Health's original plan was to use contract manufacturers in India to produce AngioDefender. It has since changed its course and is now using a Michigan-based manufacturer it found with the help of MichBio.
"As we ramp up we will be creating more work for not only us but other Michigan companies," Charlton says.
Source: Randal Charlton, director of Everist Health
Writer: Jon Zemke